While there has been a slight improvement in the availability of platinum-based chemotherapy agents, most institutions are still facing shortages and “living paycheck to paycheck” with the drugs, a survey revealed.
The National Comprehensive Cancer Network- a non-profit alliance of leading cancer centers across the United States-;has released a follow-up survey on the ongoing chemotherapy shortages: 72% of the centers surveyed continue to experience a shortage of carboplatin and 59% are still seeing a shortage of cisplatin.
/PRNewswire/ The National Comprehensive Cancer Network® (NCCN®) a non-profit alliance of leading cancer centers across the United States has released a.
Shortages of cisplatin and carboplatin have continued at the majority of National Cancer Center Network (NCCN) institutions, according to data from a follow-up survey conducted by NCCN.